$14.780
+0.823 (+5.57%)收盘时
IAM 同业对比
In the context of the broader market, IAM competes directly with industry leaders such as PRME and SANA. With a market capitalization of $700.58M, it holds a significant position in the sector. When comparing efficiency, IAM's gross margin of N/A stands against PRME's 100.00% and SANA's N/A. Such benchmarking helps identify whether Iambic Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.
Iambic Therapeutics, Inc. Common Stock 财务表现
The company shows no earnings with a P/E ratio of 0 and a forward P/E of 0, indicating it is not generating profits. Its price-to-sales ratio is quite high at 38.1, which raises concerns about valuation.
Financials
No data
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。